Janux Therapeutics Revenue

In the year 2025, Janux Therapeutics had annual revenue of $10.00M, down -5.55%.

Revenue (ttm)

$10.00M

Revenue Growth

-5.55%

P/S Ratio

81.64

Revenue / Employee

$91,743

Employees

109

Market Cap

816.36M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	10.00M	-588.00K	-5.55%
Dec 31, 2024	10.59M	2.51M	30.99%
Dec 31, 2023	8.08M	-529.00K	-6.14%
Dec 31, 2022	8.61M	4.98M	136.79%
Dec 31, 2021	3.64M	-	-
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Arvinas	262.60M
Gyre Therapeutics	107.27M
Evommune	13.00M
Prime Medicine	5.98M
KalVista Pharmaceuticals	1.43M

Revenue Rankings

JANX News

4 days ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
13 days ago - Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - Business Wire
5 weeks ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
5 weeks ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
5 weeks ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
5 weeks ago - Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire
2 months ago - Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire
3 months ago - Janux Therapeutics Stock Hits 52-Week Low After Trial Update - Benzinga

More News